SU6. Association of High Risk of Cardiovascular Disease With Increased Serum hsCRP Levels Progressively in Patients With Schizophrenia
Background: There is excess and premature mortality in schizophrenia (SZ), from both natural and unnatural causes, when compared to the general population. In a 15-year follow-up study of SZ patients, 22% had died, of which greater than 50% died from cardiovascular and respiratory diseases. Inflamma...
Saved in:
| Published in: | Schizophrenia bulletin Vol. 43; no. suppl_1; pp. S162 - S163 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
US
Oxford University Press
01-03-2017
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background:
There is excess and premature mortality in schizophrenia (SZ), from both natural and unnatural causes, when compared to the general population. In a 15-year follow-up study of SZ patients, 22% had died, of which greater than 50% died from cardiovascular and respiratory diseases. Inflammation has been linked to all stages of atherosclerosis. Recent studies suggest a role of C-reactive protein (CRP) as a risk marker for cardiovascular disease (CVD). CRP is a blood-borne protein that is produced by hepatocytes and regulated by inflammatory cytokines. The purpose of this study was to test whether high risk of cardiovascular disease was associated with increased levels of serum high-sensitivity CRP (hsCRP) progressively during the course of schizophrenia development.
Methods:
Serum hsCRP contents were compared among first-episode antipsychotic-naive patients with SZ (FEAN-SZ,
n
= 24), early course SZ patients with duration of illness < 9 years (ECSZ,
n
= 18) and those chronic SZ patients (CSZ) having mean duration of illness >20 years patients currently with (
n
= 21) and those without (
n
= 19) treatment with lipid lowering drugs (LLD). In addition, age- and gender-matched healthy control subjects (HC,
n
= 25) were used for baseline comparisons with FEAN-SZ group. The high risk of CVD in human subjects was determined according to the National Cholesterol Education Program Adult Treatment Panel III (ATP-III) guidelines. The hsCRP measures were categorized as low risk, <1 mg/l; average risk, 1–3 mg/l; and high risk, >3 mg/l.
Results:
Similar to HC subjects, 79% FEAN-SZ patients had low-risk hsCRP values with only 8% and 13% in average- and high-risk values, respectively. However, as disease progressed, 33% of clinically stable ECSZ patients who were not identified at high risk of CVD had average- and high-risk values, respectively. Among CSZ patients without LLD, 79% had high risk and 21% had average risk of hsCRP values. Following LLD therapy, these values remained relative high with 62%, 29%, and 9% in high-, average-, and low-risk hsCRP values, respectively. In addition, levels of hsCRP were inversely correlated with levels of HDL cholesterol.
Conclusion:
Our present data support the notion that the addition of hsCRP to the ATP-III global risk score provides a more accurate assessment of CVD risk in SZ patients. Serum hsCRP may also be an early marker of CVD risk in schizophrenia. On the other hand, Lp(a) levels, considering as a “Heart Attack” cholesterol and a strongly inherited risk factor for CVD, were not elevated in either ECSZ or CSZ patients in the present study. (Supported in part by the American Heart Association and MH58141 grants.) |
|---|---|
| ISSN: | 0586-7614 1745-1701 |
| DOI: | 10.1093/schbul/sbx024.005 |